Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00115)
Name |
Acute pancreatitis
|
||||
---|---|---|---|---|---|
ICD |
ICD-11: DC31
|
Full List of Target(s) of This Ferroptosis-centered Disease
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
In total 3 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Pancreatitis [ICD-11: DC31] | ||||
Responsed Drug | Ulinastatin | Phase 3 | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | 266-6 cells | Normal | Mus musculus | CVCL_3481 | |
In Vivo Model |
For cerulein-induced acute pancreatitis, male mice (age, 8-10 wk) received 7 hourly intraperitoneal injections of 50 g/kg cerulein in sterile saline. Olanzapine was repeatedly administered orally by gavage at a dose of 5 mg/kg to mice at 3 and 12 hours after the first cerulein injection, while controls were treated by oral administration with vehicle (smooth peanut butter).The parameters of acute pancreatitis were assessed 12 hours after the last cerulein treatment. For the induction of chronic pancreatitis, male mice (age, 8-10 wk) were fed a LieberDeCarli ethanol (5% vol/vol) liquid diet for 4 weeks (F1258; Bio-Serv, Flemington,NJ).In parallel, olanzapine was administered orally by gavage at a dose of 5 mg/kg to mice (3 times per week, over 4 weeks), while controls were treated by oral administration with vehicle. The parameters of chronic pancreatitis were assessed in mice 4 weeks after feeding them the LieberDeCarli ethanol liquid diet.
Click to Show/Hide
|
||||
Response regulation | Trypsin-mediated sensitization of pancreatic acinar cells to ferroptosis may be targeted for the prevention and treatment of pancreatitis in mice. Conversely, olanzapine administration protected against pancreatic ferroptotic damage and experimental pancreatitis in Gpx4-deficient mice. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [2] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Acute pancreatitis [ICD-11: DC31] | ||||
Responsed Drug | Wedelolactone | Investigative | |||
Pathway Response | Glutathione metabolism | hsa00480 | |||
Fatty acid metabolism | hsa01212 | ||||
Necroptosis | hsa04217 | ||||
Cell Process | Cell ferroptosis | ||||
Cell pyroptosis | |||||
In Vitro Model | AR42J cells | Digestive system neoplasms | Rattus norvegicus | CVCL_0143 | |
In Vivo Model |
The 8-weeks old male Sprague-Dawley rats (bodyweight 250-300 g) were purchased from Liaoning changsheng biotechnology co. LTD (Benxi, China). The rats in the taurocholate-induced acute pancreatitis group (Taur, n = 6) were fasted overnight, after anesthesia the hepatic portal of the bile duct was clamped and 3.5% sodium taurocholate (Aladdin, Shanghai, China) in a volume of 1 ml/kg were retrogradely injected into the biliopancreatic duct at a constant speed (0.1 ml/min). The rats in the Sham group (n = 6) were received the laparotomy and the same volume of saline solution. The rats in the disulfiram treatment group (Taur + Disul, n = 6) were administrated with 100 mg/kg pyroptosis antagonist disulfiram (Aladdin) by intraperitoneal (i.p.) injection before the surgery. The rats in the ferrostatin-1 treatment group (Taur + Fer-1, n = 6) were i.p. administered 2.5 mol/kg ferroptosis antagonist ferrostatin-1 (Aladdin) 1 h before the surgery.
Click to Show/Hide
|
||||
Response regulation | Wedelolactone promoted the transcriptional activity and the selenium sensitivity of GPX4. Moreover, the protective effects of Wed in caerulein-stimulated pancreatic acinar cells were markedly abrogated by the down-regulation of GPX4. Wed mitigated Acute pancreatitis (AP) and associated lung injury via GPX4 mediated suppression of pyroptosis and ferroptosis. | ||||
Experiment 3 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Pancreatitis [ICD-11: DC31] | ||||
Responsed Drug | Olanzapine | Investigative | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | 266-6 cells | Normal | Mus musculus | CVCL_3481 | |
In Vivo Model |
For cerulein-induced acute pancreatitis, male mice (age, 8-10 wk) received 7 hourly intraperitoneal injections of 50 g/kg cerulein in sterile saline. Olanzapine was repeatedly administered orally by gavage at a dose of 5 mg/kg to mice at 3 and 12 hours after the first cerulein injection, while controls were treated by oral administration with vehicle (smooth peanut butter).The parameters of acute pancreatitis were assessed 12 hours after the last cerulein treatment. For the induction of chronic pancreatitis, male mice (age, 8-10 wk) were fed a LieberDeCarli ethanol (5% vol/vol) liquid diet for 4 weeks (F1258; Bio-Serv, Flemington,NJ).In parallel, olanzapine was administered orally by gavage at a dose of 5 mg/kg to mice (3 times per week, over 4 weeks), while controls were treated by oral administration with vehicle. The parameters of chronic pancreatitis were assessed in mice 4 weeks after feeding them the LieberDeCarli ethanol liquid diet.
Click to Show/Hide
|
||||
Response regulation | Trypsin-mediated sensitization of pancreatic acinar cells to ferroptosis may be targeted for the prevention and treatment of pancreatitis in mice. Conversely, olanzapine administration protected against pancreatic ferroptotic damage and experimental pancreatitis in Gpx4-deficient mice. | ||||
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Target for Ferroptosis | Marker/Suppressor | ||||
Responsed Disease | Acute pancreatitis [ICD-11: DC31] | ||||
Responsed Drug | Ginsenoside Rg3 | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | AR42J cells | Digestive system neoplasms | Rattus norvegicus | CVCL_0143 | |
In Vivo Model |
Male C57BL/6 mice (8 weeks old; SPF; weighing 24-26 g, n = 16 in total) were purchased from SPF (Beijing) Biotechnology Co., Ltd. All mice were housed in an environmentally controlled room at a temperature ranging from 20 to 24 on a 12 h light/dark cycle and used in the experiments following an overnight fast with water, availablead libitum. All procedures followed the Principles of Laboratory Animal Care (NIH publication number 85Y23, revised in 1996), and the experimental protocol was approved by the Animal Care Committee, Nanjing Medical University (NMU-2021JK-085).
Click to Show/Hide
|
||||
Response regulation | Taken together, the present study, to the best of our knowledge, is the first to reveal a protective role for Ginsenoside Rg3 in mice with acute pancreatitis by suppressing oxidative stressrelated ferroptosis and the activation of the NRF2/HO1 pathway. | ||||
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [3] | ||||
Target for Ferroptosis | Suppressor | ||||
Responsed Disease | Acute pancreatitis [ICD-11: DC31] | ||||
Responsed Drug | Ginsenoside Rg3 | Investigative | |||
Pathway Response | Ferroptosis | hsa04216 | |||
Fatty acid metabolism | hsa01212 | ||||
Cell Process | Cell ferroptosis | ||||
In Vitro Model | AR42J cells | Digestive system neoplasms | Rattus norvegicus | CVCL_0143 | |
In Vivo Model |
Male C57BL/6 mice (8 weeks old; SPF; weighing 24-26 g, n = 16 in total) were purchased from SPF (Beijing) Biotechnology Co., Ltd. All mice were housed in an environmentally controlled room at a temperature ranging from 20 to 24 on a 12 h light/dark cycle and used in the experiments following an overnight fast with water, availablead libitum. All procedures followed the Principles of Laboratory Animal Care (NIH publication number 85Y23, revised in 1996), and the experimental protocol was approved by the Animal Care Committee, Nanjing Medical University (NMU-2021JK-085).
Click to Show/Hide
|
||||
Response regulation | Taken together, the present study, to the best of our knowledge, is the first to reveal a protective role for Ginsenoside Rg3 in mice with acute pancreatitis by suppressing oxidative stressrelated ferroptosis and the activation of the NRF2/HO1 pathway. | ||||
Unspecific Target
In total 2 item(s) under this target | |||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Responsed Disease | Pancreatitis [ICD-11: DC31] | ||||
Responsed Regulator | Hippocalcin-like protein 1 (HPCAL1) | Driver | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Autophagy | hsa04140 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | ||
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | ||
5637 cells | Bladder carcinoma | Homo sapiens | CVCL_0126 | ||
SK-OV-3 cells | Ovarian serous cystadenocarcinoma | Homo sapiens | CVCL_0532 | ||
PC-3 cells | Prostate carcinoma | Homo sapiens | CVCL_0035 | ||
In Vivo Model |
Pancreatic-specific gpx4 knockout mice were produced and identified in our laboratory by crossing floxed Gpx4 (a gift from Dr. Qitao Ran, UT Health San Antonio) and Pdx1-Cre (the Jackson Laboratory, 014647) transgenic mice (C57BL/6J background). For cerulein-induced acute pancreatitis, female mice (8-10 weeks) received seven hourly i.p. injections of 50 ug/kg cerulein in sterile saline. We repeatedly administered iHPCAL1 by i.p. at a dose of 10 mg/kg to mice at 3 and 12 h after the first cerulein injection, while controls were treated by administration with vehicle. The parameters of acute pancreatitis were assessed 12 h after the last cerulein treatment.
Click to Show/Hide
|
||||
Response regulation | HPCAL1 as a specific autophagy receptor provides the first mechanistic understanding of how CDH2 is selectively delivered to phagophores, leading to CDH2 degradation for the induction of ferroptosis. The genetic or pharmacological inhibition of HPCAL1 prevented ferroptosis-induced tumor suppression and pancreatitis in suitable mouse models. | ||||
Experiment 2 Reporting the Ferroptosis-centered Disease Response by This Target | [4] | ||||
Responsed Disease | Pancreatitis [ICD-11: DC31] | ||||
Responsed Regulator | Cadherin-2 (CDH2) | Suppressor | |||
Pathway Response | Fatty acid metabolism | hsa01212 | |||
Autophagy | hsa04140 | ||||
Cell Process | Cell ferroptosis | ||||
Cell autophagy | |||||
In Vitro Model | HT-1080 cells | Fibrosarcoma | Homo sapiens | CVCL_0317 | |
Calu-1 cells | Lung squamous cell carcinoma | Homo sapiens | CVCL_0608 | ||
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | ||
5637 cells | Bladder carcinoma | Homo sapiens | CVCL_0126 | ||
SK-OV-3 cells | Ovarian serous cystadenocarcinoma | Homo sapiens | CVCL_0532 | ||
PC-3 cells | Prostate carcinoma | Homo sapiens | CVCL_0035 | ||
In Vivo Model |
Pancreatic-specific gpx4 knockout mice were produced and identified in our laboratory by crossing floxed Gpx4 (a gift from Dr. Qitao Ran, UT Health San Antonio) and Pdx1-Cre (the Jackson Laboratory, 014647) transgenic mice (C57BL/6J background). For cerulein-induced acute pancreatitis, female mice (8-10 weeks) received seven hourly i.p. injections of 50 ug/kg cerulein in sterile saline. We repeatedly administered iHPCAL1 by i.p. at a dose of 10 mg/kg to mice at 3 and 12 h after the first cerulein injection, while controls were treated by administration with vehicle. The parameters of acute pancreatitis were assessed 12 h after the last cerulein treatment.
Click to Show/Hide
|
||||
Response regulation | HPCAL1 as a specific autophagy receptor provides the first mechanistic understanding of how CDH2 is selectively delivered to phagophores, leading to CDH2 degradation for the induction of ferroptosis. The genetic or pharmacological inhibition of HPCAL1 prevented ferroptosis-induced tumor suppression and pancreatitis in suitable mouse models. | ||||
References